The CAV1 Knockout Caco-2 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the human Caco-2 colorectal adenocarcinoma cell line. This loss-of-function model provides constitutive disruption of the CAV1 gene, which encodes caveolin-1, the principal structural and functional component of caveolae. By eliminating caveolin-1 expression, this cell line permits detailed analysis of caveolae-dependent processes in an intestinal epithelial context.
Caco-2 cells, originally isolated from a human colon carcinoma, are a well-established in vitro model of the intestinal epithelium. Upon reaching confluence, these cells spontaneously differentiate into polarized enterocyte-like monolayers that form tight junctions, develop apical microvilli, and express brush border enzymes and drug transporters characteristic of the small intestine. They are widely employed in pharmaceutical science to predict human oral drug absorption, assess intestinal permeability, and investigate epithelial barrier function. The CAV1 Knockout Caco-2 Cell Line is generated on this robust background, offering a physiologically relevant system for studying caveolin-1 biology in intestinal cells.
Caveolin-1 drives the formation of flask-shaped caveolae at the plasma membrane. It directly binds and inhibits signaling receptors, notably EGFR and eNOS, thereby attenuating downstream PI3K/AKT and MAPK cascades. Upstream regulators include EGF, TGF-??, hypoxia, nitric oxide, and the tumor suppressor p53, which transcriptionally controls caveolin-1 expression. Downstream, caveolin-1 modulates EGFR internalization, Src kinase activity, Rho GTPase signaling, ??-catenin transduction, and integrin trafficking. It interacts with cavin proteins, Src, EGFR, eNOS, Rac1, integrins, actin, and cholesterol to coordinate endocytosis, adhesion, and signal integration. CAV1 knockout disrupts caveolae structure and removes a critical brake on diverse signaling pathways.
In the Caco-2 intestinal epithelial context, CAV1 knockout disrupts caveolae and releases tonic inhibition of EGFR and eNOS, enhancing PI3K/AKT and MAPK signaling. This can alter tight junction dynamics, cell migration, and endocytic trafficking of drug transporters. Because Caco-2 cells express Wnt and TGF-?? pathway components, this model enables dissection of caveolin-1??s roles in colorectal cancer progression and epithelial?Cmesenchymal transition. The combination of relevant epithelial features and CAV1 loss makes this a powerful translational research tool.
Researchers can employ the CAV1 Knockout Caco-2 Cell Line in a wide array of functional studies. It is ideally suited for Transwell permeability assays to evaluate how caveolin-1 influences intestinal drug absorption and barrier integrity. Migration and invasion assays using these cells can reveal mechanisms of caveolin-1-dependent metastatic behavior. Biochemical analyses via western blotting for CAV1 and phospho-proteins, RT-qPCR, immunofluorescence, and co-immunoprecipitation with EGFR or cavins enable signaling dissection. Additional applications include cholesterol staining and flow cytometry to assess lipid raft organization and surface receptor expression. For further information, please contact Ascent Research.
